Mounjaro 15 mg: The Top Maintenance Dose Explained

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The Mounjaro 15 mg search usually comes from someone at or nearing the top of the titration ladder. This page reports where 15 mg sits in the FDA-approved tirzepatide schedule, what patients commonly experience there, and which symptoms should prompt a call to a provider. It offers no dosing direction of its own; that decision belongs to your prescriber. For pathway grounding, begin at the Peptides and GLP-1 Education Hub.

Where 15 mg sits in the schedule

15 mg is the highest FDA-approved maintenance dose for tirzepatide per the product label, used in Mounjaro and Zepbound. It is reached only after cumulative titration through 2.5, 5, 7.5, 10, 12.5, and finally 15 mg. Not every patient reaches this level; many meet their clinical goals at a lower maintenance dose and remain there long-term rather than climbing to the top of the ladder.

What patients commonly report at this step

Gastrointestinal effects remain the most frequently described experiences at any new step. Nausea, mild vomiting, and transient constipation or diarrhea tend to be most pronounced in the first weeks after moving up. Appetite suppression, earlier satiety, and shifting meal portions are also commonly reported. These accounts are individual, and clinical outcomes vary widely, so reaching 15 mg does not carry a guaranteed experience for anyone.

When a provider adjusts the dose

Titration intervals are specified in each product's FDA label, commonly around four weeks between steps, and the prescribing provider modifies them based on tolerability and response. Because 15 mg is the top of the schedule, adjustment here usually means staying at the dose or, if symptoms are significant, revisiting tolerability with the provider. Any change remains a clinical decision rather than a self-directed one.

Side effects to watch at any dose

The class boxed warning

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and it applies at 15 mg as at every earlier step.

When to seek care

Contact a provider for severe or persistent abdominal pain suggesting pancreatitis, right-upper-quadrant pain with fever suggesting gallbladder disease, persistent vomiting with dehydration, signs of hypoglycemia, or any allergic reaction. Severe symptoms warrant urgent or emergency care.

Reaching the top of the ladder

Because 15 mg is the highest FDA-approved maintenance dose, arriving there means there is no higher step to climb within the label. That changes the nature of the conversation with a provider: instead of planning the next increase, the discussion centers on whether the current dose is meeting goals and remaining tolerable. It is worth emphasizing that reaching 15 mg is not a target everyone is meant to hit. Many patients meet their goals at a lower maintenance dose and stay there, and remaining below the top of the ladder is a normal, provider-guided outcome rather than a shortfall.

The genetic baseline beneath the top dose

The 15 mg step is standardized, but the individual at the top of the ladder is not. Variants in MC4R, a melanocortin receptor central to satiety and energy balance, along with FTO, TCF7L2, shape appetite and energy balance well before titration begins. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights to map that terrain. It does not predict response to any dose or medication and never replaces clinical judgment. See how it pairs with the Tirzepatide Injection protocol.

The bottom line on 15 mg

At 15 mg you are at the top of the FDA-approved ladder, so the conversation shifts from planning the next increase to gauging whether the current dose meets your goals and stays tolerable. Not everyone is meant to reach this level, and settling at a lower maintenance dose is a normal, provider-guided outcome. Where the label ends, clinical judgment continues to steer.

Frequently Asked Questions

What is Mounjaro 15 mg used for?

15 mg is the highest FDA-approved maintenance dose for tirzepatide per the product label, used in Mounjaro and Zepbound. It is reached after cumulative titration through 2.5, 5, 7.5, 10, 12.5, and finally 15 mg. Not every patient reaches it; some remain at a lower maintenance dose long-term.

How long do I stay on Mounjaro 15 mg?

Titration intervals are specified in the FDA-approved label, typically a minimum of about four weeks between steps, and are modified by the prescribing provider based on tolerability and response. Because 15 mg is the top dose, many patients remain there long-term as maintenance under provider guidance.

What side effects should I watch for at 15 mg?

Gastrointestinal symptoms are most common at any step, including nausea, vomiting, diarrhea, and constipation. Contact your provider for severe abdominal pain, persistent vomiting with dehydration, right-upper-quadrant pain with fever, or any allergic reaction. Tirzepatide carries the class boxed warning for thyroid C-cell tumor risk.

Does genetic testing predict how I do at 15 mg?

No. The Precision Peptide Genetic Test does not predict response to any dose of any medication. It analyzes pathway-level variants such as FTO and MC4R, and TCF7L2 that shape baseline appetite and energy-balance biology, the upstream context that applies at every step of the schedule.

Continue through the PlexusDx Education Hub for more on tirzepatide dosing and metabolic genetics.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.